Clinical trial
Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That…
NCT00489216 · UNC Lineberger Comprehensive Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00489216 |
|---|---|
| Title | Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids |
| Official title | Weekly Subcutaneous Efalizumab for the Treatment of Steroid Refractory Graft-Versus-Host Disease of the Skin and Liver |
| Acronym | NRR |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease |
| Intervention type | Biological |
| Interventions | efalizumab |
| Enrollment | 2 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jun 21, 2007 |
| Last update posted | May 23, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: